START San Antonio's Drew Rasco, MD, reflects on the evolution of immunotherapy and highlights how novel therapies such as bispecifics are both challenging and intriguing for principal investigators (PIs).
- 5 Informed Consent Fixes For Sponsors And Investigators
- Navigating The New EU Pharmaceutical Legislation: Key Implications For Pediatric Drug Development
- Why Life Science Tech Pilots Fail After The Demo — And How To Avoid It
- The Profit Margin Double Standard That Needs To Change
- Why The Governed Hybrid Site Model Is Strategically Superior — Part 3
- Beyond The IND Clock: What Operation TrialBlazer Gets Right — And Where It Stalls (Part 1)
- Beyond The IND Clock: The Legal Architecture Of QRIs And What Industry Must Say Before July 22 (Part 2)
GUEST COLUMNISTS
-
Beyond The IND Clock: What Operation TrialBlazer Gets Right — And Where It Stalls (Part 1)
The FDA's Operation TrailBlazer includes a proposal to speed up IND review and approval. But will it work? Kimberly Chew and Odette Hauke identify where the initiative succeeds and where the structural gaps begin.
-
Beyond The IND Clock: The Legal Architecture Of QRIs And What Industry Must Say Before July 22 (Part 2)
The FDA's Operation TrailBlazer includes a proposal to speed up IND review and approval. But Kimberly Chew and Odette Hauke say its legal architecture is unresolved and reveals compliance issues that are hard to ignore.
-
Project Management And AI: What Should Be Automated And What Should Not
How can clinical research project management be optimize by AI? To determine its best fit, consultant Jason C. Bork assess AI's utility in project management through the lens of Plan, Do, Check, Act (PDCA).
-
How Clinical Research Site Operating Models Perform in Practice – Part 2
In part two of this three-part series, Paradigm Clinical Research CEO Kurt Mussina evaluates how each site operating model performs regarding speed, patient access, investigator engagement, quality, accountability, and scalability.
-
Why Operating Model Is The Next Competitive Frontier In Clinical Research Site Strategy – Part 1
In this three-part series, Paradigm Clinical Research CEO Kurt Mussina discusses the meaningfulness of a site's operating model to clinical trial sponsors. In part one, he first defines operating model types.
-
Before AI Can Transform Clinical Trials, It Needs More Patient Data
King’s College London Professor Maddy Parsons says AI won't improve clinical trials — unless researchers begin collecting richer biological data, embracing diversity, and treating every clinical trial as learning opportunity.
-
How One Researcher's Personal Study Experience Is Helping Him Better Serve Patients
Regeneron Executive Director in Clinical Sciences Kaniel Cassady, Ph.D., reflects on how his industry experience shaped his expectations, questions, and interactions as a patient in a clinical trial and how his patient experience is reshaping his clinical work going forward.
-
i-Cubed Used End-To-End AI In A Proof-Of-Concept Trial. Here's What They Learned
Discover how well AI fared in document generation, patient engagement, data integration, and more in an end-to-end proof-of-concept study run by i-Cubed.
CLINICAL TRIAL WHITE PAPERS
-
Faster Starts, Stronger Finish: Operational Excellence In NSCLC
In NSCLC trials, data‑driven site selection, streamlined protocols, efficient screening strategies, and proactive engagement can accelerate enrollment and improve trial efficiency across regions.
-
Gene Therapies For Rare Diseases: Platforms, Modalities, And Delivery Systems10/6/2025
Examine the treatment landscape for rare diseases and the rapid evolution of gene therapy across three key dimensions: editing platforms, delivery modalities, and delivery vehicles.
-
Rewriting The Future Of Clinical Trials8/8/2025
In an increasingly data-complex environment, eCOA is emerging as a foundational pillar for both operational agility and scientific rigor in clinical development
-
Remote Patient Monitoring Using Mobile Health Technology3/28/2025
This study investigates the attitudes of cancer patients towards the adoption of mHealth technologies, including applications and wearable devices, for monitoring purposes during or after their treatment.
-
Antibody-Drug Conjugates: 'Magic Bullets' Become Reality2/19/2025
Cancer therapy has evolved from potent chemotherapy to targeted biological therapy, including antibody-drug conjugates (ADCs). Learn more about ADCs’ makeup, mechanisms, and the development landscape.
-
Modernizing Clinical Trial Oversight: The Path To Clinical Operations Excellence8/4/2025
Examine the current state of RBQM approaches to virtualizing clinical oversight, and the value that adopting these approaches brings to sponsors, CROs, sites, and ultimately patients.
CLINICAL TRIAL APP NOTES & CASE STUDIES
-
How A Leading Chinese Biopharmaceutical Company Modernized Clinical Operations7/15/2026
A growing biopharma pipeline needed better document oversight. Learn how automation and centralized tracking improved compliance and trial visibility.
-
Partnership Driving Superior Enrollment And Speed In Phase III Trial1/31/2025
Examine the partnership between CRIO and Sitero, including how it underscores the significant impact of technology in optimizing trial performance and accelerating treatment development.
-
Cracking The Code: Strategies For Success In Complex Trials8/27/2024
Navigating the complexities of modern clinical trials requires advanced technology and strategic planning. Learn what goes into managing a challenging, decentralized rare disease trial.
-
Urgent Compliance Recovery Following Vendor Transition5/26/2026
Rapid local leadership, clear ownership of corrective actions, and governed oversight enabled time‑critical remediation of legacy safety gaps, restoring regulatory confidence and protecting market continuity under intense inspection pressure.
-
Duchenne Muscular Dystrophy Trial In China9/17/2025
A global sponsor conducting a Duchenne Muscular Dystrophy trial in China required reliable patient travel solutions to support children and families.
-
Scaling Global Vaccine Mega-Trials For A Top Five Pharma4/16/2026
See how high-volume enrollment, dynamic safety data capture, and rapid iteration can support global studies operating under intense timelines and scale.
NEWSLETTER ARCHIVE
- What Operation TrialBlazer Gets Right — And Where It Stalls
- 07.15.26 -- Improve Patient Retention, Rapid Study Design, And Monitoring Quality
- 07.14.26 -- A Role-Play Conference Session That Reframes The Data Manager's Job
- 07.14.26 -- How Life Sciences Leaders Are Building Scalable Operations
- 07.13.26 -- Safer ADCs- Enabling Higher Effective Dosing
RECRUITMENT AND DIVERSITY
This section includes some helpful resources regarding patient recruitment and diversity in clinical trials, including this link to the FDA's guidance on diversity action plans.
-
Informed consent has never been solely about documentation, but some sponsors has treated it as a checkbox exercise. Here, consultant Tasha Mohseni shares tips and fixs for how best to approach informed consent.
-
Regeneron Executive Director in Clinical Sciences Kaniel Cassady, Ph.D., reflects on how his industry experience shaped his expectations, questions, and interactions as a patient in a clinical trial and how his patient experience is reshaping his clinical work going forward.
-
AI is changing the way clinical trial trials are discussed, planned, and designed. But even with an improved protocol, are AI-enhanced trials driving better enrollment?
FOCUS ON PATIENTS
-
Digital twins can transform trial design by making data more robust and alleviating patient burden. In this interview, Epicrispr CEO Amber Salzman, Ph.D., shares how the company's using it to reliably predict muscle volume change in their trial for a FSHD gene therapy.
-
Regeneron Executive Director in Clinical Sciences Kaniel Cassady, Ph.D., reflects on how his industry experience shaped his expectations, questions, and interactions as a patient in a clinical trial and how his patient experience is reshaping his clinical work going forward.
-
The American Diabetes Association 2026 conference showed where we are and where we're going with GLP-1 therapies.